|
Name |
Cyclo(Ile-Leu-Leu-Leu-Leu-)
|
| Molecular Formula | C30H55N5O5 | |
| IUPAC Name* |
(3S,6S,9S,12S,15S)-3-[(2S)-butan-2-yl]-6,9,12,15-tetrakis(2-methylpropyl)-1,4,7,10,13-pentazacyclopentadecane-2,5,8,11,14-pentone
|
|
| SMILES |
CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(C)C)CC(C)C)CC(C)C)CC(C)C
|
|
| InChI |
InChI=1S/C30H55N5O5/c1-11-20(10)25-30(40)34-23(14-18(6)7)28(38)32-21(12-16(2)3)26(36)31-22(13-17(4)5)27(37)33-24(15-19(8)9)29(39)35-25/h16-25H,11-15H2,1-10H3,(H,31,36)(H,32,38)(H,33,37)(H,34,40)(H,35,39)/t20-,21-,22-,23-,24-,25-/m0/s1
|
|
| InChIKey |
MEJHOHNWGFEFFZ-OOPVGHQCSA-N
|
|
| Synonyms |
Cyclo(Ile-Leu-Leu-Leu-Leu-); Cyclo-(L-Ile-L-Leu-L-Leu-L-Leu-L-Leu)
|
|
| CAS | NA | |
| PubChem CID | 102342363 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 565.8 | ALogp: | 5.3 |
| HBD: | 5 | HBA: | 5 |
| Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 146.0 | Aromatic Rings: | 1 |
| Heavy Atoms: | 40 | QED Weighted: | 0.275 |
| Caco-2 Permeability: | -5.135 | MDCK Permeability: | 0.00007150 |
| Pgp-inhibitor: | 0.996 | Pgp-substrate: | 0.664 |
| Human Intestinal Absorption (HIA): | 0.016 | 20% Bioavailability (F20%): | 0.993 |
| 30% Bioavailability (F30%): | 0.632 |
| Blood-Brain-Barrier Penetration (BBB): | 0.034 | Plasma Protein Binding (PPB): | 84.32% |
| Volume Distribution (VD): | 0.553 | Fu: | 2.10% |
| CYP1A2-inhibitor: | 0.005 | CYP1A2-substrate: | 0.03 |
| CYP2C19-inhibitor: | 0.295 | CYP2C19-substrate: | 0.063 |
| CYP2C9-inhibitor: | 0.415 | CYP2C9-substrate: | 0.078 |
| CYP2D6-inhibitor: | 0.05 | CYP2D6-substrate: | 0.089 |
| CYP3A4-inhibitor: | 0.8 | CYP3A4-substrate: | 0.15 |
| Clearance (CL): | 4.302 | Half-life (T1/2): | 0.335 |
| hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.834 |
| Drug-inuced Liver Injury (DILI): | 0.051 | AMES Toxicity: | 0.013 |
| Rat Oral Acute Toxicity: | 0.692 | Maximum Recommended Daily Dose: | 0.142 |
| Skin Sensitization: | 0.048 | Carcinogencity: | 0.092 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
| Respiratory Toxicity: | 0.038 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004731 | ![]() |
0.622 | D0K7NQ | ![]() |
0.364 | ||
| ENC005469 | ![]() |
0.519 | D0J7XL | ![]() |
0.346 | ||
| ENC003175 | ![]() |
0.519 | D02SBQ | ![]() |
0.318 | ||
| ENC002910 | ![]() |
0.500 | D0O3YF | ![]() |
0.317 | ||
| ENC001983 | ![]() |
0.485 | D0L9HX | ![]() |
0.313 | ||
| ENC002373 | ![]() |
0.441 | D0M3FJ | ![]() |
0.309 | ||
| ENC002515 | ![]() |
0.402 | D09OOV | ![]() |
0.286 | ||
| ENC000990 | ![]() |
0.400 | D08FJL | ![]() |
0.281 | ||
| ENC002212 | ![]() |
0.400 | D0Q3BV | ![]() |
0.278 | ||
| ENC002514 | ![]() |
0.388 | D0D8XY | ![]() |
0.271 | ||